Toned-Down Proposal on “Precursor” Premium Still Leaves CSIMC Wary; 10% Tabled with Strings Attached
To read the full story
Related Article
- New Combination Drugs Containing Non-Innovative APIs Should Be Priced Based on Prices of Other APIs Contained: CSIMC Subcommittee
November 29, 2013
- CSIMC Bill Payer Rep Repeats Opposition to Replacing Special Price Cut for Off-Patent Drugs with New Rule
November 28, 2013
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
REGULATORY
- Japan Pharma Subgroup Talks to Feed into Pricing, Budget Debates
November 16, 2026
- Japan Names 38 Top-Rated Generic Makers for Stable Supply
November 16, 2026
- Pharma Calls for Drug Price Hikes, Govt Purchases to Spur MCM Investment
November 16, 2026
- Stable Supply Drives Japan’s Generic Drug Delistings: Jiho Tally
November 16, 2026
- Optimal Use Guidelines Issued for Vyepti; Updates for Leqembi, Kisunla, Keytruda
November 13, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





